Palisade Bio, Inc. announced on July 9, 2025, the appointment of Emil Chuang, MB BS FRACP, to its Board of Directors. Dr. Chuang is a pediatric gastroenterologist with nearly 25 years of pharmaceutical and clinical experience, including leadership roles in IBD programs and two successful regulatory approvals.
Dr. Chuang's expertise spans from preclinical translational medicine through Phase 1-4 clinical development, with significant contributions to programs targeting inflammatory bowel diseases (IBD) such as infliximab and vedolizumab. His appointment is expected to provide valuable insight as the company executes its clinical programs.
Palisade Bio aims to leverage Dr. Chuang's deep understanding of IBD and clinical trial design to advance its pipeline, particularly PALI-2108 for Fibrostenotic Crohn’s Disease and Ulcerative Colitis. This strategic addition strengthens the company's leadership in a competitive biopharmaceutical market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.